Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2005
10/18/2005CA2282082C Microgranules containing cisplatin
10/18/2005CA2152507C Novel combination of benzoquinazoline antifolates and protecting agents
10/18/2005CA2148928C Pharmacologically active pyridine derivatives and processes for the preparation thereof
10/18/2005CA2033640C Vaccines against cancer and infectious diseases
10/18/2005CA2006929C Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs
10/15/2005CA2464687A1 Spirastrellolides, antimitotic macrolides and analogues; and pharmaceutical compositions and research tools thereof
10/13/2005WO2005099727A1 Drug
10/13/2005WO2005095613A1 Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
10/13/2005WO2005095612A1 Gene encoding guanine nucleotide exchange factor and gene product thereof
10/13/2005WO2005095604A1 Rf rp transgenic animal
10/13/2005WO2005095600A1 Heparin-binding protein having heparan sulfate sugar chain attached thereto, process for producing the same and medicinal composition containing the same
10/13/2005WO2005095598A1 Cancer antigen peptide originating in wt1
10/13/2005WO2005095458A1 CHIMERIC MONOCLONAL ANTIBODY FOR BINDING WITH HIGH AFFINITY SELECTIVELY TO hCG
10/13/2005WO2005095456A1 An gene enginf; ering recombinant anti-cea, anti-cd3 and anti-cd28 single-chain tri-specific antibody
10/13/2005WO2005095443A1 Drug delivery system using peptide modification
10/13/2005WO2005095419A1 Thiazolopyrimidine derivative
10/13/2005WO2005095413A1 Antitumor agent
10/13/2005WO2005095412A1 Antiallergic agent
10/13/2005WO2005095399A2 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
10/13/2005WO2005095389A1 Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
10/13/2005WO2005095382A1 Anti-tumor agent
10/13/2005WO2005095381A1 Dipeptidyl peptidase inhibitors
10/13/2005WO2005095375A1 Extract of sophora flavescens flavonoids and uses thereof
10/13/2005WO2005095369A1 Water soluble esters of [n-(4-amino-2-butynyl)] with anticancer activity
10/13/2005WO2005095356A1 Agent for generating heat or singlet oxygen and composition for cancer treatment each comprising organic peroxide or chemiluminescent compound
10/13/2005WO2005095341A1 Nitrogen-containing heterocyclic compound
10/13/2005WO2005094900A1 Preventive and/or remedy for cancer
10/13/2005WO2005094899A1 Clusterin antisense therapy for treatment of cancer
10/13/2005WO2005094887A1 sFRP EXPRESSION POTENTIATING AGENT
10/13/2005WO2005094881A1 Antibody drug
10/13/2005WO2005094878A1 Composition having antitumor effect
10/13/2005WO2005094867A1 Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment
10/13/2005WO2005094823A1 Flt-3 INHIBITOR
10/13/2005WO2005026741B1 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
10/13/2005WO2005025552A3 Protein binding compounds
10/13/2005WO2003068954A8 Microorganism for genetic therapeutic treatment of proliferative diseases
10/13/2005US20050228180 Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228055 Substituted nitrobenzene derivatives as pharmaceutical and other uses athereof
10/13/2005US20050228053 Atamestane and toremifene dosage forms and kits for use treating breast cancer
10/13/2005US20050228039 Luminacin analogs and uses thereof
10/13/2005US20050228036 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
10/13/2005US20050228033 Voltage-gated sodium channel (VGSC) and prostate voltage sodium channel (PVSC) inhibitors for treating diseases characterized by overabundant or hyperactive VGSC/PVSC's; phenytoin derivatives; use as sodium channel blockers, anti-cancer agents; can be used to limit or prevent PSA growth and metastasis
10/13/2005US20050228025 Substituted oxindole derivatives as tyrosine kinase inhibitors
10/13/2005US20050228018 Chemical compounds
10/13/2005US20050228017 Novel anticancer compounds
10/13/2005US20050228011 use of carboxy-functional benzofurans or benzothiophenes to treat tumor growth, metastasis, osteoporosis, restenosis, inflammation, macular degeneration, diabetic retinopathy, rheumatoid arthritis, and sickle cell anemia; greater bioavailability or fewer side-effects
10/13/2005US20050228005 Protein kinase inhibitors and uses thereof
10/13/2005US20050228003 Mitotic kinesin inhibitors
10/13/2005US20050227997 Selective inhibition of aggrecanase in osteoarthritis treatment
10/13/2005US20050227991 Containing a piperazine ring, e.g., N'-(4-{4-[5-(1,2-dithiolan-3-yl)pentanoyl]-1-piperazinyl)phenyl)-2-thiophenecarboximidamide and intermediates for preparing them; useful for inhibiting NO synthase and regenerating antioxidants
10/13/2005US20050227988 compounds capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases; gliomas, meningomas, cancers, Hodgkin's disease, retinal vascularization; core structure that comprises a benzazocine moiety
10/13/2005US20050227983 Triazine compounds and their analogs, compositions, and methods
10/13/2005US20050227973 Human adam-10 inhibitors
10/13/2005US20050227972 treating disorders of the cardiovascular system; adenosine receptor agonists/antagonists
10/13/2005US20050227963 Antiinflammatory agents
10/13/2005US20050227951 Verification of translation
10/13/2005US20050227948 Hif hydroxylase inhibitors
10/13/2005US20050227910 Local regional chemotherapy and radiotherapy using in situ hydrogel
10/13/2005US20050227354 Using fibronectin nutrient broth to propagate cytotoxic lymphocyte with enhanced interleukin-2 receptor expression profiles; immunotherapy; antitumor agents
10/13/2005US20050227282 Human extracellular matrix-1
10/13/2005US20050227280 Proteases
10/13/2005US20050227277 Apoptosis proteins
10/13/2005US20050227249 Polymorphisms in the human MDR-1 gene and their use in diagnostic and therapeutic applications
10/13/2005US20050227245 Reagents and methods for identifying and modulating expression of genes regulated by retinoids
10/13/2005US20050226940 Antitumour compositions containing taxane derivatives
10/13/2005US20050226885 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
10/13/2005US20050226884 Using monoclonal antibody as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders; immunotherapy
10/13/2005US20050226880 Use of a preparation based on an antibody directed against a tumor-associated glycosylation
10/13/2005US20050226877 administration of a function blocking antibody which is capable of binding an epitope of VLA-1; arthritis
10/13/2005US20050226874 Point mutations; immunology
10/13/2005US20050226859 Peg-Modified Uricase
10/13/2005US20050226849 Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses
10/13/2005US20050226813 Labelled somatostatin analogs backbone cyclized through metal complexation
10/13/2005US20050223628 Fuel additive
10/13/2005CA2563103A1 Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer
10/13/2005CA2562700A1 Novel pharmaceutical compositions
10/13/2005CA2561977A1 Substituted thiophene derivatives as anti-cancer agents
10/13/2005CA2561835A1 Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
10/13/2005CA2561732A1 Antibody drug
10/13/2005CA2561516A1 Combinations of signal transduction inhibitors
10/13/2005CA2561417A1 Novel thiazolopyrazoles and methods of their use
10/13/2005CA2560822A1 Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
10/13/2005CA2560691A1 Tricyclic pyrazole kinase inhibitors
10/13/2005CA2558923A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
10/13/2005CA2557402A1 Pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
10/13/2005CA2557393A1 Oxidized thioether derivatives of styryl-azoles and their use as her tyrosine kinases inhibitors
10/13/2005CA2556227A1 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
10/13/2005CA2545512A1 Methods of identifying neoplasm-specific antibodies and uses thereof
10/13/2005CA2499113A1 Medicinal product
10/12/2005EP1584925A1 Novel screening method
10/12/2005EP1584685A2 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
10/12/2005EP1584682A1 Regulation of bcl-2 gene expression
10/12/2005EP1584627A1 Dimerized peptide
10/12/2005EP1584619A1 Derivatives of quinoline as inhibitors for MEK
10/12/2005EP1583772A2 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability
10/12/2005EP1583755A1 Thiophene-carboxamide derivatives and their use as inhibitors of the enzime ikk-2
10/12/2005EP1583744A2 Substituted benzylamine derivatives and methods of use
10/12/2005EP1583736A1 Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
10/12/2005EP1583553A2 Therapeutic use of modulators of notch
1 ... 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 ... 2211